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ARTIKEL PENELITIAN
ABSTRACT
We conducted open label, non-comparative trial in patients aged > 60 with advanced and intermediate-grade Non-
Hodgkin Lymphoma (NHL) (stadium II, III, IV) to evaluate the efficacy and safety of In-Asia-manufactured rhG-CSF 300
mcg for prevention of CHOP (cyclophosphamide, doxorubicin, vincristine) chemotherapy-induced severe neutropenia.
Primary prophylaxis with this in-Asia-manufactured rhG-CSF 300 mcg could reduce median duration of grade 4
neutropenia in cycle 1 and cycle 2 to three days and of grade 3 neutropenia in cycle 1 to two days and in cycle 2 to
two half days from four and five days median duration of grade 4 and 3 neutropenia without rhG-CSF respectively.
Febrile neutropenia was occurred in seven patients who received in-Asia-manufactured rhG-CSF 300 mcg (24.1%),
lower than if rhG-CSF was not given (31.3-34% FN). Three patients (10.3 %) who received in-Asia-manufactured rhG-CSF
300 mcg were hospitalized due to febrile neutropenia, lower than if rhG-CSF was not given (24-28% hospitalized due
to febrile neutropenia). Mostly reported adverse events were nausea and vomiting which were occurred in nine
patients (31.0%). In conclusion, the use of in-Asia-manufactured rhG-CSF 300 mcg for primary prophylaxis in elderly
patients with non-Hodgkin lymphoma receiving CHOP chemotherapy could reduce the duration of neutropenia,
reduce the rate of febrile neutropenia (FN) and febrile neutropenia hospitalization (FNH).
ABSTRAK
Penelitian open-label, non-komparatif ini dilakukan untuk mengevaluasi efektivitas dan keamanan recombinant human
G-CSF produksi Asia sebagai profilaksis primer dalam pencegahan neutropenia derajat berat pada pasien usia lanjut
(>60 tahun) dengan limfoma non-Hodgkin (LNH) derajat sedang dan lanjut (stadium II,III,IV) yang mendapat terapi
CHOP (siklofosfamid, doksorubisin, vinkristin). Profilaksis primer recombinant human G-CSF (rhG-CSF) produksi Asia
dapat mengurangi median durasi neutropenia derajat 4 pada siklus sitostatistika ke-1 dan ke-2 menjadi tiga hari,
sementara median durasi neutropenia derajat 3 pada siklus sitostistika ke-1 menjadi dua hari dan pada siklus
sitostatistika ke-2 menjadi dua setengah hari, dari median durasi neutropenia grade 4 dan grade 3 tanpa G-CSF, yaitu
empat dan lima hari berurutan. Febrile neutropenia ditemukan pada 7 pasien yang mendapat rhG-CSF produksi Asia
(24.1%), lebih rendah jika dibandingkan studi tanpa rhG-CFS (31.3-34% FN). Tiga pasien mendapat rhG-CSF produksi
Asia (10,3%) dirawat inap akibat febrile neutropenia, lebih rendah jika dibandingkan rawat inap pada studi tanpa rhG-
CSF (24-28%). Kejadian yang tidak diinginkan terbanyak adalah mual dan muntah yang terjadi pada 9 (31%) pasien.
Sebagai kesimpulan, penggunaan rhG-CSF produksi Asia untuk profilaksis primer pada pasien LNH usia lanjut yang
mendapat regimen CHOP dapat mengurangi durasi neutropenia, mengurangi kejadian febrile neutropenia, dan angka
rawat inap akibat febrile neutropenia.
Kata kunci : Efektivitas, keamanan, G-CSF, LNH pada usia lanjut
CORRESPONDENCE TO:
Prof. DR. Dr.Arry
Haryanto Reksodiputro,
SpPD, KHOM
Hematology-oncology
sub Division
Cipto Mangunkusumo
Hospital Indonesia
JL. Diponegoro No.71
Jakarta Pusat
Telp/Fax : 62 21
3926286/3142697
E-mail:
homfkui@hotmail.com
Efficacy and Safety of In-Asia-Manufactured
rhG-CSF 300 mcg As Primary Prophylaxis for
Prevention of CHOP Chemotherapy-induced
Severe Neutropenia in Elderly Patients with
Lymphoma Non-Hodgkin
Investigators:
A.Harryanto Reksodiputro, Zubairi Djoerban, Karmel L. Tambunan, Abdulmuthalib, Aru W. Sudoyo,
Abidin Widjanarko, Djumhana Atmakusuma, Syafrizal Syafei, Nugroho Prayogo, Ronald Hukom, 
Dody Ranuhardy,  Zakifman Jack, Asrul Harsal, Noorwati S, Bambang Karsono, Shufrie Effendi,
Cosphiadi Irawan, Hilman Tadjoedin, Martin Batubara, Diana Paramitha, Nuzirwan Acang, Mediarty,
Iman Supandiman, Rahmat Sumantri, Trinugroho Heri Fadjari, Pandji Irani Wianza, Amaylia Oehadian,
C. Suharti, Mika L. Tobing, Elias Pardjono, Adiwijono, Johan Kurnianda, Boediwarsono, Soebandiri,
Sugiyanto, Ami Ashariati, Budi Darmawan Machsoosh, I Made Bakta, Tjok Gde Darmayudha, Ketut
Suega, Andi Fahruddin Benyamin, Harlinda Kumaat, Linda Rotty, Muhammad Darwin Prenggono
10 Indonesian Journal of Cancer Vol. III, No. 1      Januari - Maret 2009
Efficacy and Safety of In-Asia-Manufactured rhG-CSF 300 mcg As Primary Prophylaxis for Prevention of CHOP Chemotherapy-induced Severe Neutropenia in Elderly
Patients with Lymphoma Non-Hodgkin 9√15
INTRODUCTION
Non-Hodgkin Lymphoma (NHL) remains a deadlymalignancy, primarily affecting the elderly (61% were
age >60 years).1 CHOP therapy, the standard curative
treatment for NHL patients, consists of cyclophospha-
mide 750 mg/m2, doxorubicin 50 mg/m2, and vincristine
1.4 mg/m2 (maximum dose, 2.0 mg), was given intra-
venously on day 1, together with prednisone 60-100
mg/m2 (per oral) PO on day 1-5, administered every 21
days for 6-8 cycles.2-5 However, standard-dose of CHOP
used to treat lymphoma can cause many side effects. The
most serious side effect is neutropenia. The incidence of
neutropenia is higher in the elderly as reported by
Morrison et al., i.e. 34% in older patients compared with
21% in below 65 years (P<.05).6
Studies show that the best long-term outcome was
reached if patients receive the full dose of chemotherapy
on time at every cycle. Most delay and reduction in the
planned doses of chemotherapy were due to its side
effect. Several retrospective studies on NHL chemo-
therapy showed that dose reductions of 20% to 30% have
been associated with lower complete response rates
and/or reduced survival.7-11 Chemotherapy-induced
neutropenia could reduce the dose intensity of CHOP
therapy or delay chemotherapy schedule. Severe
neutropenia can be also life threatening due to increasing
risk for infection and sepsis. Studies have described a
large percentage of neutropenia-related deaths within the
first two cycles of therapy.12,13 
The American Society of Clinical Oncology (ASCO)
recommends the prophylactic use of G-CSF for patients
receiving standard doses of chemotherapy as primary
and secondary prophylaxis of febrile neutropenia to
ensure that they can receive chemotherapy treatment at
the planned dose and schedule. Primary prophylaxis of
human recombinant G-CSF refers to the use of the growth
factor before any occurrence of neutropenia. Secondary
prophylaxis refers to its use in subsequent chemotherapy
cycles after the occurrence of neutropenia in at least one
of the preceding cycles.14,15 Primary prophylaxis is
recommended for the prevention of febrile neutropenia
in patients with high risk of febrile neutropenia based on
age, medical history, disease characteristics and
myelotoxicity of chemotherapy regimen or special
circumstances, such as patients who receive relative non-
myelosuppressive chemotherapy but have potential risk
factors for febrile neutropenia or infection due to bone
marrow compromise or co-morbidity.
Even though recombinant human G-CSF preparation
is already available in Indonesia, but its use is limited due
to the high-price and low affordability of the most
population. However, rapid progress of biotechnology in
Asian country makes such biotechnology products are
now also produced in a more affordable price. The aim of
this study was to evaluate the efficacy and safety of rhG-
CSF 300 mcg manufactured in Asia for prevention of
severe neutropenia resulted from CHOP chemotherapy in
elderly patients with non-Hodgkin lymphoma. We also
monitored adverse events occurred during this in-Asia-
manufactured rhG-CSF 300 mcg therapy.
MATERI AND METHOD
Patients Characteristics
We conducted an open label, non-comparative trial
from July 2003 to September 2004. Patients who were
eligible for the trial were patients, aged more than 60,
with advanced-stage and intermediate-grade NHL
(stadium II, III, IV) determined by histology and
cytology examination, which have baseline leukocyte
count >3,000/μ l  or neutrophil count >1,500/μ l ,
thrombocytes >100,000/μl, performance status ECOG
<2, life survival >6 months, and received standard
CHOP regiment. Patients, who were contraindicated
for rhG-CSF, had received autologous/allogeneic stem
cells, were pregnant and lactating, were excluded from
the study. 
Methods
In-Asia-manufactured rhG-CSF 300 mcg was given on
the second day post-chemotherapy cycle 1 and 2 with the
dose of 5 μg/kg BW once daily for 14 days. Concomitant
therapy was paracetamol 500 mg three times daily and
methylprednisolone 4 mg twice daily (08.00 AM and
08.00 PM).
Laboratory examination was done everyday during In-
Asia-manufactured rhG-CSF 300 mcg therapy including
hemoglobin, hematocrit, leucocyte count, neutrophil
count, thrombocyte count, and white blood cell. C-
reactive protein and thorax X-ray were examined if there
was suspicion of infection (Table 1).
Adverse event, such as bone pain, nausea, vomiting,
abdominal pain, rash, thrombocytopenia, and other
adverse events were closely monitored and documented
during study period. Physical and vital sign examinations
were also done routinely during In-Asia-manufactured
rhG-CSF 300 mcg therapy in order to detect any change in
patient condition and any sign of focal infection. 
Statistical Analysis
This non-comparative trial was using descriptive
method. Baseline characteristics, the incidence of
neutropenia (in percentage), severity (day of nadir
absolute neutrophil count [ANC]) and duration of
neutropenia (in days) were presented in numbers and
graphics. The percentage of each grade neutropenia,
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febrile neutropenia hospitalization rate, clinical infection
rate, adverse event rate were also described. 
RESULTS
Patient Characteristics
Between November 2003 and October 2005, 38
patients with non-Hodgkin lymphoma were screened and
recruited to the study. Of these 38 patients, six patients
were excluded from the study. Data from a total 32
patients were available for baseline analysis. Three
patients were dropped out at the beginning of the study
and left out for main analysis of cycle 1 since they could
not contribute for outcome analysis. Another three
patients dropped out during cycle 1 and six patients did
not start cycle 2, leaving 20 patients available for analysis
at cycle 2.
The proportion of male (53.1%) is slightly higher than
female (46.9%). Patients were between 60 to 75 years-old
(mean: 67.1 years). The majority had body mass index
(BMI), calculated as weight in kilograms divided by the
square of height in meters, ranged between normal to
underweight (96.6% with BMI below 24.9) which is a
characteristic for cancer patients. Baseline demographic
characteristics of the study participants are described in
table 2.
Duration of Neutropenia
The median duration of grade 4 neutropenia in cycle 1
and cycle 2 was three days. The median duration of grade
3 neutropenia in cycle 1 was two days and in cycle 2 was
two half days (Table 3). Changes of absolute neutrophil
count (ANC) day-by-day throughout the study showed a
marked variation between patients. Figure 1 shows
example of representative individual graph during CHOP
and In-Asia-manufactured rhG-CSF 300 mcg therapy from
4 patients
Among 29 patients who received this In-Asia-
manufactured rhG-CSF 300 mcg, 3 (10.3 %) required
hospitalization due to febrile neutropenia. Among those
3 patients, 1 patient had septicemia and died due to
Table 2: Baseline demographic characteristic of study participants
Male, N (%) 17 (53.1)
Age, mean, years 67.1
Weight, mean (SD), kg 49.2 (9.7)
Height, mean (SD), cm 156.1 (8.2)
BMI, mean (SD), kg/m2 20.2 (2.9)
Underweight, N (%) 11 (51.7)
With significant comorbidity, N (%) 7 (21.9)
Table 4: Incidence of clinical infection
Clinical infection N (%)
Febrile neutropenia 7 (24.1)
Respiratory tract symptoms, cough 3 (10.3)
GI tract symptoms, diarrhea 2 (6.9)
Septicemia 1 (3.5)
Table 5: adverse events occurred during cycle 1 and cycle 2 of CHOP
treatment
Non-hematological symptoms N(%)
Nausea or vomiting 9 (31.0)
Dyspepsia 5 (17.2)
Asthenia or weakness 6 (20.7)
Neuropathy 3 (10.3)
Bone pain 2 (6.9)
Constipation 1 (3.5)
Table 3: Duration and percentage of neutropenia in cycle 1 and cycle 2
Grade of 
neutropenia N % of Mean Standard Median Minimum Maximum
in Cycle 1 Total N Deviation
0 4 13.8 % 0.00 0.000 0.00 0 0
1 2 6.9% 1.00 0.000 1.00 1 1
2 1 3.4% 2.00 - 2.00 2 2
3 1 3.4% 2.00 - 2.00 2 2
4 21 72.4% 3.48 0.281 3.00 2 7
Total 29 100.0% 2.72 0.317 3.00 0 7
Grade of 
neutropenia N % of Mean Standard Median Minimum Maximum
in Cycle Total N Deviation
0 4 20.0 % 0.00 0.000 0.00 0 0
2 2 10.0% 2.00 0.000 2.00 2 2
3 2 10.0% 2.50 0.707 2.50 2 3
4 12 60.0% 3.25 1.138 3.00 1 6
Total 20 100.0% 2.40 1.569 3.00 0 6
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septic shock. Clinical infection observed during CHOP
and this In-Asia-manufactured rhG-CSF 300 mcg therapy
were reported in Table 4.
Adverse Events
Mostly reported side effects were nausea or vomiting
which were occurred in 9 (31.0%) patients. Other non-
hematological toxicities were dyspepsia or heartburn,
asthenia or weakness, neuropathy, skeletal pain, and
constipation (Table 5).
DISCUSSION
In this study, we found that this In-Asia-manufactured
rhG-CSF 300 mcg could shorten the median duration of
grade 3 and 4 neutropenia. In similar study conducted by
Hartman et al.,17 patients receiving standard chemo-
therapy without rhG-CSF had grade 4 and 3 neutropenia
with median duration of four and five days, respectively.
Whereas patients receiving standard chemotherapy with
rhG-CSF had grade 4 and 3 neutropenia with median
duration two days and three days, respectively. Primary
prophylaxis with this In-Asia-manufactured rhG-CSF 300
mcg has reduced median duration of grade 4 neutropenia
in cycle 1 and cycle 2 to three days and of grade 3
neutropenia in cycle 1 to two days and in cycle 2 to two
half days.
As a preventive treatment adjunct to chemotherapy,
rhG-CSF has been shown to shorten the neutropenic
period and to reduce the incidence of febrile neutropenia
in high-risk patients.18-20 Several risk factors associated
with development of chemotherapy-induced neutropenia
including age,21 performance status,22 medical
comorbidities,23 laboratory abnormalities,22 and tumor
type.23 Elderly patients tend to have more limited
hematopoietic reserve than younger patients do, and are
therefore more susceptible to chemotherapy-induced
myelosuppression than younger are. This was seen in our
study which had slightly longer median duration time of
neutropenia in patients who were given In-Asia-
manufactured rhG-CSF 300 mcg, when compared with
median duration time of neutropenia in patients who
were given rhG-CSF in study conducted by Hartman et
al17. The explanation for this result is because our study
only included subject above 65 years, 51.7% were
underweight, and 21.9% had significant comorbidity
whereas in Hartman study included patients above 21
years and 81% were in 0-1 (fully functional to good)
peformance score.
rhG-CSF has more clinical benefit if given as
prophylaxis as shown in eight randomized, controlled
Figure 1:  Individual Absolute Neutrophil Count Graphic During CHOP and rhG-CSF 300 mcg Therapy
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trials (RCTs) on GM-CSF,24-28 G-CSF,29,30 or both31 as
treatment in febrile patients with chemotherapy-induced
neutropenia. The largest was an Australian multi-center
trial of 218 patients receiving rhG-CSF (12 μg/kg/day, by
continuous subcutaneous infusion) or placebo, along with
intravenous antibiotics. In this Australian trial, treatment
of febrile neutropenia patients with rhG-CSF could
reduced duration of neutropenia by one day, but the
duration of fever, duration of antibiotic therapy, and
median period of hospitalization were not affected,
despite continuous infusion of rhG-CSF at a dose more
than twice that routinely used in practice.29
In our study, with in-Asia-manufactured rhG-CSF 300
mcg primary prophylaxis, there were only 10.3% patients
who were hospitalized due to febrile neutropenia. This
was in accordance with Hartman et al. and other study
which showed 10-15% hospitalization for febrile
neutropenia.35,36 In study done by Chrischilles,33 the
effect of full-dose CHOP in intermediate NHL patients
without rhG-CSF, causing febrile neutropenia hospi-
talization (FNH) in 28% of patients 65 years of age or
greater. In the Oncology Practice Patterns (OPP) study
analyzing patterns of CHOP or CNOP (cyclophospamide,
Novantrone, vincristine) chemotherapy in 492 patients
with intermediate NHL showed 24% patients without rhG-
CSF were hospitalized for febrile neutropenia.34
The OPP study showed that primary prophylactic of
rhG-CSF was associated with a significant reduction in the
incidence of hospitalizations for febrile neutropenia (FN)
in all patients receiving appropriate chemotherapeutic
dose intensity. The risk of hospitalization of FN in the
study was significantly associated with the following
characteristics: age 65 years or older, serum albumin level
at presentation less than or equal to 3.5 g/dL, planned
average relative dose intensity greater than or equal to
80%, baseline absolute neutrophil count less than
1500/mm3, and the presence of hepatic disease.32
Clinical infection that mostly occurred in this study
was febrile neutropenia (24.1%), whereas Morrison et al.
reported that the incidence of FN without rhG-CSF
prophylaxis was 34%.37 In OPP study the rate of febrile
neutropenia without rhG-CSF prophylaxis was 31.3%.36
The prophylactic rhG-CSF would be clinically effective
when the risk of febrile neutropenia is 20%. A major
change in the 2006 ASCO guidelines for white-cell growth
factors is to recommend use of rhG-CSF or granulocyte-
macrophage colony-stimulating factor (GM-CSF) when the
risk of FN is approximately 20%, rather than 40% as in the
1996, 1997, and 2000 guidelines.42 The National Com-
prehensive Cancer Center Network (NCCN) also recently
revised their own guidelines in favor of a 20% FN
threshold for a definite indication of granulocyte colony-
stimulating factor (G-CSF) prophylaxis and a 10% to 20%
FN threshold range indicating optional rhG-CSF
prophylaxis.39 This change is based largely on two new
phase III clinical trials that show rhG-CSFs are effective
when the risk of FN is approximately 20%.40,41 In the first
study, Vogel et al. compared patients with breast cancer
treated with docetaxel 100 mg/m2 with or without
pegylated rhG-CSF; the risk of FN was reduced from 17%
without rhG-CSF to 1% with rhG-CSF, and the risk of
hospitalization for FN was reduced from 14% without
rhG-CSF to 1% with rhGCSF.40 A second study by Timmer-
Bonte et al. showed that the risk of FN in small-cell lung
cancer (SCLC) patients at high risk of FN could be re-
duced from 24% to 10% in cycle 1 by adding rhG-CSF.41
Although this regimen is not widely used in the United
States, the SCLC and breast cancer trials showed that
rhG-CSFs reduce the risk of FN, even when that risk is
relatively low. 
As noted in the NCCN guidelines, when costs are
considered, the economic impact of FN becomes greater,
and the cost-saving benefits of rhG-CSF are more
apparent. Economic analysis from Timmer-Bonte et al.
confirms the NCCN assessments of rhG-CSF use. Adding
rhG-CSF to antibiotic prophylaxis increased per-patient
cost in the European setting by $650 (US) in the first cycle
and $5,000 overall.41 However, prophylactic regimens
and reduced toxicity appear more cost effective in the
United States, where costs of each episode of FN can be
four times greater than in Europe because of markedly
greater healthcare and hospital expenditures.42 In
addition, the indirect costs of FN can be substantial. It is
entirely possible that, in the United States, rhG-CSF use
for primary prophylaxis in the setting of cancer
chemotherapies associated with a 20% rate of FN may be
both clinically effective and also cost effective. Based on
this economic analysis, this In-Asia-manufactured rhG-
CSF 300 mcg would be more cost effective for the
patients and this product has also shown comparable
clinical benefit as other preparations of rhG-CSF.
Most adverse events in the use of rhG-CSF were
attributed to the underlying malignancy or cytotoxic
chemotherapy. In the study to evaluate the efficacy and
safety of Filgrastrim, these adverse events occurred at
rates between 2% to 57% included nausea/vomiting,
skeletal pain, alopecia, diarrhoea, neutropenic fever,
mucositis, fever, fatigue, anorexia, dyspnea, headache,
cough, skin rash, chest pain, chest pain, generalized
weakness, sore throat, stomatitis, constipation and
unspecified pain. The highest rate of adverse event was
nausea/vomiting, the lowest rate adverse event was
unspecified pain. In our study, the highest rate of adverse
event was also nausea or vomiting (31%), whereas bone
pain only occurred in 6.9% patients. In the meta-analysis
of prophylactic rhG-CFS, the mean frequency of bone
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pain among patients receiving this growth factor was 21%
(17-25%).43
In conclusion, the use of In-Asia-manufactured rhG-
CSF 300 mcg for primary prophylaxis in patients with
CHOP therapy could reduce the duration of neutropenia,
reduce the rate of febrile neutropenia event and febrile
neutropenia hospitalization, which were in accordance
with other trial using rhG-CSF. The lack of this study was
the study designed as open label and non-comparative.
Therefore, a trial with higher level of evidence based
medicine such as RCT design needs to be done in the next
future. <
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